158 filings
8-K
KZR
Kezar Life Sciences Inc
4 Jun 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
10-Q
2024 Q1
KZR
Kezar Life Sciences Inc
Quarterly report
9 May 24
4:08pm
8-K
KZR
Kezar Life Sciences Inc
9 May 24
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:04pm
ARS
2023 FY
KZR
Kezar Life Sciences Inc
26 Apr 24
Annual report to shareholders
4:12pm
DEFA14A
KZR
Kezar Life Sciences Inc
26 Apr 24
Additional proxy soliciting materials
4:10pm
424B5
vr2qe6ni4c39 41jvo
22 Mar 24
Prospectus supplement for primary offering
4:05pm
S-8
owasztjm 710q6
14 Mar 24
Registration of securities for employees
4:33pm
8-K
v4kpgoj25
14 Mar 24
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
4:04pm
8-K
e6z1 5m59t4836se
8 Jan 24
Results of Operations and Financial Condition
8:36am
8-K
icz7o2sxbl 657
4 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:28pm
8-K
der0mhxc
13 Nov 23
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
12:00am
8-K
c08o17tho5xql
27 Oct 23
Departure of Directors or Certain Officers
4:06pm
8-K
30tmk6mo5m3 ry
3 Oct 23
Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026
4:14pm
8-K
7eyzrs ldy94e
20 Sep 23
Entry into a Material Definitive Agreement
6:40pm
8-K
74yxj4dy cc
11 Aug 23
Other Events
5:52pm